Traslational hematology
Scientic Supervisor / Contact Person
Name and Surname
Joaquín Martínez-López
Localization & Research Area
Faculty / Institute
Faculty of Medicine
Department
Hospital 12 de Octubre, Hematology
Research Area
Life Sciences (LIF)
MSCA & ERC experience
Research group / research team hosted any MSCA fellow?
No
Research group / research team have any ERC beneficiaries?
No
Research Team & Research Topic
Research Team / Research Group Name (if any)
Traslational hematology
Brief description of the Research Team / Research Group / Department
The Haematological Malignancies Clinical Research Unit focuses on three main objectives.
Molecular research of haematological cancer: the study of cancerinduced changes at the proteomic and genomic levels. We aim to:
i) find new genomic and proteomic biomarkers for a better diagnosis of these haematological diseases;
ii) identify new molecular alterations as predictors of response to a treatment, for example by study ingminimal residual disease; and
iii) study immune mechanisms of cancer control, with a special focus on NK cells.
In vitro research:
i) establish the effects of new anticancer molecules in in vitro models of the disease;
ii) determine the mechanisms of resistance to anticancer drugs.
Clinical research: translate preclinical findings to benefit patients through a phase I clinical trials unit.
Molecular research of haematological cancer: the study of cancerinduced changes at the proteomic and genomic levels. We aim to:
i) find new genomic and proteomic biomarkers for a better diagnosis of these haematological diseases;
ii) identify new molecular alterations as predictors of response to a treatment, for example by study ingminimal residual disease; and
iii) study immune mechanisms of cancer control, with a special focus on NK cells.
In vitro research:
i) establish the effects of new anticancer molecules in in vitro models of the disease;
ii) determine the mechanisms of resistance to anticancer drugs.
Clinical research: translate preclinical findings to benefit patients through a phase I clinical trials unit.
Research lines / projects proposed
Molecular research of haematological cancer: the study of cancerinduced changes at the proteomic and genomic levels. We aim to:
i) find new genomic and proteomic biomarkers for a better diagnosis of these haematological diseases;
ii) identify new molecular alterations as predictors of response to a treatment, for example by study ingminimal residual disease; and
iii) study immune mechanisms of cancer control, with a special focus on NK cells.
In vitro research:
i) establish the effects of new anticancer molecules in in vitro models of the disease;
ii) determine the mechanisms of resistance to anticancer drugs.
Clinical research: translate preclinical findings to benefit patients through a phase I clinical trials unit.
i) find new genomic and proteomic biomarkers for a better diagnosis of these haematological diseases;
ii) identify new molecular alterations as predictors of response to a treatment, for example by study ingminimal residual disease; and
iii) study immune mechanisms of cancer control, with a special focus on NK cells.
In vitro research:
i) establish the effects of new anticancer molecules in in vitro models of the disease;
ii) determine the mechanisms of resistance to anticancer drugs.
Clinical research: translate preclinical findings to benefit patients through a phase I clinical trials unit.
Application requirements
One Page Proposal
You can attach the 'One Page Proposal' to enhance the attractiveness of your application. Supervisors usually appreciate it. Please take into account your background and the information provided in Research Team & Research Topic section to fill in it.
Submit an application
Forms
Popular
-
José Manuel Udías Moinelo
-
Life Sciences (LIF), Physics (PHY)
-
Faculty of Physical Science
Popular
-
Gonzalo Carracedo
-
Life Sciences (LIF)
-
Faculty of Optics and Optometry
Popular
-
Juan Borrero Del Pino
-
Life Sciences (LIF)
-
Faculty of Veterinary Medicine